{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T17:04:24Z","timestamp":1784221464420,"version":"3.55.0"},"reference-count":34,"publisher":"Society of Nuclear Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2026,6,22]]},"DOI":"10.2967\/jnumed.126.272368","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T16:15:26Z","timestamp":1784218526000},"page":"jnumed.126.272368","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic Value of a Composite Score Incorporating Baseline [\n                    <sup>18<\/sup>\n                    F]FDG PET\/CT and [\n                    <sup>68<\/sup>\n                    Ga]Ga-PSMA-11 PET\/CT When Screening for [\n                    <sup>177<\/sup>\n                    Lu]Lu-PSMA Treatment Eligibility (PROFILE Study)"],"prefix":"10.2967","author":[{"given":"Adrien","family":"Jougla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prescillia","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laure","family":"Giraudet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Cochet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Ladoire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Vrigneaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavinia","family":"Vija-Racaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Drouet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"2026071609152260000_jnumed.126.272368v1.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2026071609152260000_jnumed.126.272368v1.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00237-3"},{"key":"2026071609152260000_jnumed.126.272368v1.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00529-6"},{"key":"2026071609152260000_jnumed.126.272368v1.4","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.112.114116"},{"key":"2026071609152260000_jnumed.126.272368v1.5","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.3390\/cancers13174270","article-title":"Development of discordant hypermetabolic prostate cancer lesions in the course of [177Lu]PSMA radioligand therapy and their possible influence on patient outcome","volume":"13","author":"Hartrampf","year":"2021","journal-title":"Cancers (Basel)."},{"key":"2026071609152260000_jnumed.126.272368v1.6","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1007\/s00259-020-05160-8","article-title":"Prognostic implications of dual tracer PET\/CT: PSMA ligand and [18F]FDG PET\/CT in patients undergoing [177Lu]PSMA radioligand therapy","volume":"48","author":"Michalski","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026071609152260000_jnumed.126.272368v1.7","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000003307"},{"key":"2026071609152260000_jnumed.126.272368v1.8","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268167"},{"key":"2026071609152260000_jnumed.126.272368v1.9","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1148\/radiol.2016142043","article-title":"Practical PERCIST: a simplified guide to PET response criteria in solid tumors 1.0","volume":"280","author":"O","year":"2016","journal-title":"Radiology."},{"key":"2026071609152260000_jnumed.126.272368v1.10","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1007\/s00259-020-04723-z","article-title":"Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617","volume":"47","author":"Ferdinandus","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026071609152260000_jnumed.126.272368v1.11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00274-6"},{"key":"2026071609152260000_jnumed.126.272368v1.12","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.224055"},{"key":"2026071609152260000_jnumed.126.272368v1.13","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.265242"},{"key":"2026071609152260000_jnumed.126.272368v1.14","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.267014"},{"key":"2026071609152260000_jnumed.126.272368v1.15","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","article-title":"Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2)","volume":"83","author":"Seifert","year":"2023","journal-title":"Eur Urol."},{"key":"2026071609152260000_jnumed.126.272368v1.16","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4"},{"key":"2026071609152260000_jnumed.126.272368v1.17","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/pros.24518","article-title":"Prognostic factors of overall and prostate-specific antigen-progression-free survival in metastatic castration-resistant prostate cancer patients treated with 177Lu-PSMA-617. A single-center prospective observational study","volume":"83","author":"Telli","year":"2023","journal-title":"Prostate."},{"key":"2026071609152260000_jnumed.126.272368v1.18","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1007\/s00259-025-07198-y","article-title":"Prognostic value of [18F]FDG- and PSMA-PET in patients evaluated for [177Lu]Lu-PSMA therapy of mCRPC","volume":"52","author":"Telli","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026071609152260000_jnumed.126.272368v1.19","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.125.270804"},{"key":"2026071609152260000_jnumed.126.272368v1.20","doi-asserted-by":"crossref","first-page":"178611","DOI":"10.1016\/j.ejphar.2026.178611","article-title":"Metabolic crosstalk in the metastatic prostate cancer\u2013bone microenvironment: mechanism, detection and therapeutic strategies","volume":"1016","author":"Zheng","year":"2026","journal-title":"Eur J Pharmacol."},{"key":"2026071609152260000_jnumed.126.272368v1.21","doi-asserted-by":"crossref","first-page":"1339160","DOI":"10.3389\/fmed.2023.1339160","article-title":"Change of glucometabolic activity per PSMA expression predicts survival in mCRPC patients non-responding to PSMA radioligand therapy: introducing a novel dual imaging biomarker","volume":"10","author":"Burgard","year":"2023","journal-title":"Front Med (Lausanne)."},{"key":"2026071609152260000_jnumed.126.272368v1.22","doi-asserted-by":"crossref","first-page":"11271","DOI":"10.1038\/s41598-024-61961-z","article-title":"Dual FDG\/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT","volume":"14","author":"Rosar","year":"2024","journal-title":"Sci Rep."},{"key":"2026071609152260000_jnumed.126.272368v1.23","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.233460"},{"key":"2026071609152260000_jnumed.126.272368v1.24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40658-019-0253-z","article-title":"Multicentre quantitative 68Ga PET\/CT performance harmonisation","volume":"6","author":"Huizing","year":"2019","journal-title":"EJNMMI Phys."},{"key":"2026071609152260000_jnumed.126.272368v1.25","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.202861"},{"key":"2026071609152260000_jnumed.126.272368v1.26","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ejmp.2019.03.006","article-title":"Underestimation of 68Ga PET\/CT SUV caused by activity overestimation using default calibrator settings","volume":"59","author":"Sanderson","year":"2019","journal-title":"Phys Med."},{"key":"2026071609152260000_jnumed.126.272368v1.27","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-024-00900-z"},{"key":"2026071609152260000_jnumed.126.272368v1.28","doi-asserted-by":"publisher","DOI":"10.2967\/jnmt.125.271978"},{"key":"2026071609152260000_jnumed.126.272368v1.29","doi-asserted-by":"crossref","first-page":"102862","DOI":"10.1016\/j.eclinm.2024.102862","article-title":"Multivariable models of outcomes with [177Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial","volume":"77","author":"Herrmann","year":"2024","journal-title":"EClinicalMedicine."},{"key":"2026071609152260000_jnumed.126.272368v1.30","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05525-7"},{"key":"2026071609152260000_jnumed.126.272368v1.31","doi-asserted-by":"crossref","first-page":"e0307826","DOI":"10.1371\/journal.pone.0307826","article-title":"Prognostic value of baseline alkaline phosphatase of 177Lu\u2010PSMA radioligand therapy in metastatic castration\u2010resistant prostate cancer: a systematic review and meta\u2010analysis","volume":"19","author":"Zhang","year":"2024","journal-title":"PLoS One."},{"key":"2026071609152260000_jnumed.126.272368v1.32","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1007\/s00259-022-05853-2","article-title":"Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [177Lu]Lu-PSMA I&T during long-term follow-up","volume":"49","author":"Hartrampf","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026071609152260000_jnumed.126.272368v1.33","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.125.271825"},{"key":"2026071609152260000_jnumed.126.272368v1.34","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-017-3740-2"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.126.272368","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T16:15:29Z","timestamp":1784218529000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.126.272368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":34,"alternative-id":["10.2967\/jnumed.126.272368"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.126.272368","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]}}}